Rice Hall James & Associates LLC Takes Position in AtriCure, Inc. $ATRC

Rice Hall James & Associates LLC purchased a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,210 shares of the medical device company’s stock, valued at approximately $719,000.

Other hedge funds have also recently bought and sold shares of the company. Geneos Wealth Management Inc. acquired a new stake in AtriCure in the 2nd quarter valued at about $37,000. Smartleaf Asset Management LLC raised its stake in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after buying an additional 429 shares during the period. Fifth Third Bancorp acquired a new stake in shares of AtriCure in the first quarter valued at approximately $51,000. Global Retirement Partners LLC bought a new position in shares of AtriCure during the 4th quarter worth approximately $73,000. Finally, State of Wyoming acquired a new position in shares of AtriCure during the 4th quarter worth approximately $75,000. 99.11% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Karen Prange sold 3,000 shares of AtriCure stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total value of $85,950.00. Following the completion of the transaction, the director directly owned 26,373 shares of the company’s stock, valued at approximately $755,586.45. This trade represents a 10.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.00% of the company’s stock.

AtriCure Price Performance

AtriCure stock opened at $35.04 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.18 and a current ratio of 4.29. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $43.18. The stock has a market capitalization of $1.77 billion, a P/E ratio of 166.87 and a beta of 1.24. The stock has a fifty day moving average of $30.05 and a 200-day moving average of $31.36.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.37%. The company had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same period in the previous year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, sell-side analysts expect that AtriCure, Inc. will post 0.13 earnings per share for the current fiscal year.

AtriCure News Roundup

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Q2 earnings of $0.18 per share beat the $0.03 consensus and improved from a loss a year ago, showing a meaningful profitability turnaround. AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Revenue of $153.6 million topped Wall Street estimates of $151.8 million, reinforcing that demand remains solid. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company lifted FY2026 EPS guidance to $0.24-$0.32, well above the prior consensus, and revenue guidance of $602 million-$610 million is also near or slightly above expectations. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management described the quarter as one of “healthy growth” and a “significant step up in profitability,” which supports the recent stock strength. AtriCure Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Short-interest data showed 0 reported shares, so it does not appear to be a meaningful trading catalyst.

Analysts Set New Price Targets

Several research firms have commented on ATRC. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday, July 21st. Weiss Ratings downgraded AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Finally, Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $49.12.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.